Unknown

Dataset Information

0

Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug.


ABSTRACT: Cisplatin and other DNA-damaging chemotherapeutics are widely used to treat a broad spectrum of malignancies. However, their application is limited by both intrinsic and acquired chemoresistance. Most mutations that result from DNA damage are the consequence of error-prone translesion DNA synthesis, which could be responsible for the acquired resistance against DNA-damaging agents. Recent studies have shown that the suppression of crucial gene products (e.g., REV1, REV3L) involved in the error-prone translesion DNA synthesis pathway can sensitize intrinsically resistant tumors to chemotherapy and reduce the frequency of acquired drug resistance of relapsed tumors. In this context, combining conventional DNA-damaging chemotherapy with siRNA-based therapeutics represents a promising strategy for treating patients with malignancies. To this end, we developed a versatile nanoparticle (NP) platform to deliver a cisplatin prodrug and REV1/REV3L-specific siRNAs simultaneously to the same tumor cells. NPs are formulated through self-assembly of a biodegradable poly(lactide-coglycolide)-b-poly(ethylene glycol) diblock copolymer and a self-synthesized cationic lipid. We demonstrated the potency of the siRNA-containing NPs to knock down target genes efficiently both in vitro and in vivo. The therapeutic efficacy of NPs containing both cisplatin prodrug and REV1/REV3L-specific siRNAs was further investigated in vitro and in vivo. Quantitative real-time PCR results showed that the NPs exhibited a significant and sustained suppression of both genes in tumors for up to 3 d after a single dose. Administering these NPs revealed a synergistic effect on tumor inhibition in a human Lymph Node Carcinoma of the Prostate xenograft mouse model that was strikingly more effective than platinum monotherapy.

SUBMITTER: Xu X 

PROVIDER: S-EPMC3832000 | biostudies-literature | 2013 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug.

Xu Xiaoyang X   Xie Kun K   Zhang Xue-Qing XQ   Pridgen Eric M EM   Park Ga Young GY   Cui Danica S DS   Shi Jinjun J   Shi Jinjun J   Wu Jun J   Kantoff Philip W PW   Lippard Stephen J SJ   Langer Robert R   Walker Graham C GC   Farokhzad Omid C OC  

Proceedings of the National Academy of Sciences of the United States of America 20131028 46


Cisplatin and other DNA-damaging chemotherapeutics are widely used to treat a broad spectrum of malignancies. However, their application is limited by both intrinsic and acquired chemoresistance. Most mutations that result from DNA damage are the consequence of error-prone translesion DNA synthesis, which could be responsible for the acquired resistance against DNA-damaging agents. Recent studies have shown that the suppression of crucial gene products (e.g., REV1, REV3L) involved in the error-p  ...[more]

Similar Datasets

2022-11-18 | GSE214881 | GEO
| S-EPMC2683142 | biostudies-literature
| S-EPMC3734668 | biostudies-literature
| S-EPMC6186509 | biostudies-literature
| S-EPMC5072529 | biostudies-literature
| S-EPMC3396465 | biostudies-literature
| S-EPMC3594183 | biostudies-literature
| S-EPMC4013830 | biostudies-literature
| S-EPMC2682897 | biostudies-literature
| S-EPMC6801091 | biostudies-literature